Impact of Pretransplantation 18F-fluorodeoxy Glucose–Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Year: 2015
Type: article
Study design: Observational Study
Abstract: Assessment with (18)F-fluorodeoxy glucose (FDG)-positron emission tomography (PET) before hematopoietic cell transplantation (HCT) for lymphoma may be prognostic for outcomes. Patients with chemotherapy-sensitive non-Hodgkin lymphoma (NHL) undergoing allogeneic HCT reported to the Center of International Blood and Marrow Transplantation Registry between 2007 and 2012 were included. Pre-HCT PET status (positive versus negative) was determined by the reporting transplantation centers. We analyzed 336 patients; median age was 55 years and 60% were males. Follicular lymphoma (n = 104) was more common than large cell (n = 85), mantle cell (n = 69), and mature natural killer or T cell lymphoma (n = 78); two thirds of the cohort received reduced-intensity conditioning; one half had unrelated donor grafts. Patients underwent PET scanning a median of 1 month (range, .07 to 2.83 months) before HCT; 159 were PET positive and 177 were PET negative. At 3 years, relapse/progression, progression-free survival (PFS), and overall survival (OS) in PET-positive versus PET-negative groups were 40% versus 26%; P = .007; 43% versus 47%; P = .47; and 58% versus 60%; P = .73, respectively. On multivariate analysis, a positive pretransplantation PET was associated with an increased risk of relapse/progression (risk ratio [RR], 1.86; P = .001) but was not associated with increased mortality (RR, 1.29, 95% confidence interval [CI], .96 to 1.7; P = .08), therapy failure (RR, 1.32; 95% CI, .95 to 1.84; P = .10), or nonrelapse mortality (RR, .75; 95% CI, .48 to 1.18; P = .22). PET status conferred no influence on graft-versus-host disease. A positive PET scan before HCT is associated with increased relapse risk but should not be interpreted as a barrier to a successful allograft. PET status does not appear to predict survival after allogeneic HCT for NHL.
Authors: Veronika Bachanova, Linda J. Burns, Kwang Woo Ahn, Ginna G. Laport, Görgün Akpek, Mohamed A. Kharfan-Dabaja, Taiga Nishihori, Edward Agura, Philippe Armand, Samantha M. Jaglowski, Mitchell S. Cairo, Amanda F. Cashen, Jonathon B. Cohen, Anita D'Souza, César O. Freytes, Robert Peter Gale, Siddhartha Ganguly, Nilanjan Ghosh, Leona A. Holmberg, David J. Inwards, Abraham S. Kanate, Hillard M. Lazarus, Adriana K. Malone, Reinhold Munker, Alberto Mussetti, Maxim Norkin, Tim D. Prestidge, Jacob M. Rowe, Prakash Satwani, Tanya Siddiqi, Patrick J. Stiff, Basem M. William, Baldeep Wirk, David G. Maloney, Sonali M. Smith, Anna M. Sureda, Jeanette Carreras, Mehdi Hamadani
Institutions: University of Minnesota, University of Minnesota Medical Center, National Marrow Donor Program, Medical College of Wisconsin, Stanford Health Care, Stanford Medicine, Stanford University, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Baylor University Medical Center, Dana-Farber Cancer Institute, The Ohio State University Wexner Medical Center, The Ohio State University, New York Medical College, Barnes-Jewish Hospital, Emory University, Winship Cancer Institute, The University of Texas at San Antonio Health Science Center, South Texas Veterans Health Care System, Imperial College London, University of Kansas Medical Center, Carolinas Healthcare System, Levine Cancer Institute, Fred Hutch Cancer Center, Mayo Clinic, West Virginia University, University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Louisiana State University, Louisiana State University Health Sciences Center Shreveport, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Florida Health, University of Florida, Starship Children's Health, Shaare Zedek Medical Center, Bikur Cholim Hospital, Columbia University Irving Medical Center, Columbia University, City Of Hope National Medical Center, Loyola University Medical Center, Loyola University Chicago, Seattle Cancer Care Alliance, University of Chicago, Institut Català d'Oncologia, Duran i Reynals Hospital
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
Funders: National Marrow Donor Program, Roswell Park Cancer Institute, Be The Match Foundation, Amgen, GlaxoSmithKline, Merck, Sanofi, WellPoint, Leukemia and Lymphoma Society, Health Research, Fred Hutchinson Cancer Research Center, St. Baldrick's Foundation, Ariad Pharmaceuticals, Celgene, HistoGenetics, Osiris Therapeutics, Tarix Pharmaceuticals, Therakos, University of Minnesota, Blue Cross and Blue Shield Association, University of Utah, StemCyte, Medical College of Wisconsin, Otsuka America Pharmaceutical, Sigma-Tau Pharmaceuticals, Seattle Genetics, Actinium Pharmaceuticals, Chimerix, Incyte, Kiadis Pharma, Miltenyi Biotec, Swedish Orphan Biovitrum, Medac, National Institutes of Health, Genentech, Terumo BCT, Onyx Pharmaceuticals, U.S. Public Health Service, Allos Therapeutics, National Heart, Lung, and Blood Institute, Office of Naval Research, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences
Awards: G1328211321, University of Minnesota Clinical and Translational Science Institute (UMN CTSI), G2108949772, G2220088171, G541973719, BMT Clinical Research Network Data Coordinating Center, G7088928756, G772794905, G777363952, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research
OpenAlex ID: W1503923315